Home › Autism Spectrum Disorder › NCT06006637
Integrated Platform for Measuring and Reducing Symptoms of Autism Spectrum Disorder
Recruiting
Who can join
Ages 2 to 8 · All sexes
Full eligibility criteria
Inclusion Criteria: * Ages 2 - 8 * Autism spectrum disorder diagnosis * CARS-2 score of 30 - 45 Exclusion Criteria: * CARS scores less than 30 or over 45. * Taking psychotropic medications. * Having skin lesions on scalp * Having history of seizures * Having history of abnormal EEG * Being a relative of the PI or a researcher * Having implanted devices (including cochlear implants).
About the study
This study will consist of a randomized, double-blind, sham-controlled clinical trial at SUNY Upstate Medical University and Mt. Sinai Medical Center with 80 autistic children evaluating the effects of transcranial photobiomodulation (tPBM) on multiple clinically validated scales.
What is being tested
- Cognilum TM: Light Treatment Condition (device)
Sponsor: State University of New York - Upstate Medical University · Participants: 80 · Started: Oct 17, 2023
Contact the study team
- William E Sullivan, PhD · Phone: 315-464-3932
- Henry S Roane, PhD · Phone: 315-464-3555
Official record on ClinicalTrials.gov — NCT06006637
Locations in the U.S.
| New York | Mt. Sinai Medical Center, New York Golisano Center for Special Needs, Syracuse |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.